drugset / Trial / NCT00920699
Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)
Phase 2
Completed
90 enrolled
Johns Hopkins University
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To establish the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10 in pre-manifest participants carrying the CAGn expansion for Huntington's Disease (HD).
Timeline
- Start
- 2010-02
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coenzyme Q10 | Other / unclassified | 600 mg | Oral |
| Subject | Coenzyme Q10 | Other / unclassified | 1200 mg | Oral |
| Subject | Coenzyme Q10 | Other / unclassified | 2400 mg | Oral |